In last trading session, Esperion Therapeutics Inc. (NASDAQ:ESPR) saw 2.9 million shares changing hands with its beta currently measuring 0.89. Company’s recent per share price level of $2.04 trading at $0.07 or 3.55% at ring of the bell on the day assigns it a market valuation of $347.66M. That closing price of ESPR’s stock is at a discount of -66.67% from its 52-week high price of $3.40 and is indicating a premium of 65.69% from its 52-week low price of $0.70. Taking a look at company’s average trading volume volume of 6.16 million if we extend that period to 3-months.
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
Upright in the green during last session for gaining 3.55%, in the last five days ESPR remained trading in the red while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $2.04 price level, adding 3.77% to its value on the day. Esperion Therapeutics Inc.’s shares saw a change of -31.77% in year-to-date performance and have moved -4.23% in past 5-day. Esperion Therapeutics Inc. (NASDAQ:ESPR) showed a performance of -29.17% in past 30-days.
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Statistics highlight that Esperion Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 146.88% of value to its shares in past 6 months, showing an annual growth rate of 66.50% while that of industry is 11.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 106.30% in the current quarter and calculating 54.30% increase in the next quarter. This year revenue growth is estimated to rise 127.90% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $84.51 million for the same. And 8 analysts are in estimates of company making revenue of $42.53 million in the next quarter that will end on Jun 2024. Company posted $24.33 million and $25.79 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 247.40% while estimating it to be 64.90% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 23.09% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 80.93% while estimates for its earnings growth in next 5 years are of 16.90%.
ESPR Dividends
Esperion Therapeutics Inc. is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
